respiratory
Asthma

Dupilumab benefits extend to the long-term: TRAVERSE

New data support the long-term use of dupilumab in adult and adolescent patients with moderate-to-severe asthma. TRAVERSE, an extension trial funded by Sanofi and Regeneron Pharmaceuticals, assessed the safety and efficacy of extended dupilumab use in 2,282 adults and adolescents across 27 countries who had taken part in prior studies with the drug. Patients were ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic